Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Dynavax Technologies reports strong Q4 earnings, eyes continued growth

Dynavax Technologies showcased robust financial performance, driven by the success of HEPLISAV-B and CpG 1018 adjuvant. Progress in clinical development and market share growth were notable achievements. Challenges include maintaining market growth amidst competition and regulatory changes, while opportunities exist in expanding product revenue and advancing vaccine programs.

Dynavax reports record revenue growth, eyes market expansion opportunities

Dynavax Technologies showcased robust performance in Q1 2023, driven by record revenue growth and strong financial results.
While facing challenges such as uncertainties and competition, the company's strategic strengths and opportunities position it for continued success.
Management's focus on innovation, market expansion, and financial stability bodes well for future growth and shareholder value.
Overall, Dynavax Technologies remains optimistic about its outlook, supported by a dedicated team and a solid commercialization strategy.

Dynavax reports strong Q2 earnings, eyes growth through innovation

Dynavax Technologies delivered robust financial results in Q2 2023, driven by strong HEPLISAV-B revenue growth and increased market share.
The company's focus on innovation, market expansion, and financial stability positions it well for future growth and strategic opportunities.
While facing challenges in revenue sustainability and competition, Dynavax's strengths in market penetration and product pipeline offer avenues for continued success.
By leveraging opportunities in market expansion, product diversification, and strategic partnerships, Dynavax can further solidify its position in the vaccine and infectious disease spaces.

Dynavax reports record revenue growth and raises full-year guidance

Dynavax Technologies delivered a strong performance in Q3 2023, driven by record HEPLISAV-B revenue and market share gains.
While facing margin pressures from increasing expenses, the company's strategic focus on diversification and innovation bodes well for future growth.
With raised revenue guidance, a robust clinical pipeline, and a solid financial position, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports record revenue growth and strategic investments

Dynavax Technologies' Q4 2023 earnings call highlighted robust revenue growth, market leadership, and strategic investments in HEPLISAV-B.
The company's financial outlook for 2024, including revenue guidance and expense projections, reflects a balanced approach to growth and profitability.
With a strong cash position, ongoing pipeline developments, and focus on cost management, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports robust Q1 earnings and growth outlook

Dynavax Technologies delivered solid financial results in Q1 2024, driven by continued growth in HEPLISAV-B net product revenue and a focus on innovation and R&D advancement.
Despite market challenges and expenses, the company's strong cash position, market leadership, and upcoming milestones position it well for sustainable growth and success.
With a clear strategic focus on driving growth, maintaining market share, and advancing its vaccine portfolio, Dynavax is poised for a promising future in the healthcare industry.

Dynavax reports record sales and market share gains in Q2 2024

Dynavax Technologies delivered strong financial performance in Q2 2024, driven by record HEPLISAV-B sales and market share gains.
The company's pipeline progress and robust cash position position it well for future growth and innovation.
While challenges in managing expenses persist, strategic opportunities and a positive outlook for HEPLISAV-B offer avenues for sustained success.
Dynavax's focus on cost management, market expansion, and product development will be key to capitalizing on opportunities and overcoming challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Integral Ad Science Holding LLC

Kratos Defense & Security Solutions

IAS, DVAS and KTOS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 4, 2023.

Best Momentum Stocks to Buy for August 4th

CVR Energy

Eventbrite

J & J Snack Foods

CVI, JJSF, IAS, DVAX and EB have been added to the Zacks Rank #1 (Strong Buy) List on August 4, 2023.

New Strong Buy Stocks for August 4th

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $0.86 per share a year ago.

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates

Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Paul Cox - VP of IR and Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - CFO Conference Call Participants Matthew Phipps - William Blair Ernesto Rodriguez-Dumont - TD Cowen Roy Buchanan - JMP Securities Jonathan Miller - Evercore ISI Operator Good day ladies and gentlemen, and welcome to Dynavax Technologies' Second Quarter 2023 Financial Results. As a reminder, this conference is being recorded.

Dynavax Technologies Corporation (DVAX) Q2 2023 Earnings Call Transcript

Generated record quarterly HEPLISAV-B ® vaccine net product revenue of $56 million, a 73% year-over-year increase Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million, compared to prior range of $165 - $185 million Cash and investments increased to $682 million at quarter end; expects positive free cash flow for full year Conference call today at 4:30 p.m. ET/1:30 p.m.

Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance

EMERYVILLE, Calif. , July 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2023 financial results on Thursday, August 3, 2023, after the U.S. financial markets close.

Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023

The consensus price target hints at an 80.2% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 80.16%: Read This Before Placing a Bet

Dynavax Technologies (DVAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Dynavax Technologies (DVAX) Soars 5.6%: Is Further Upside Left in the Stock?

Enerplus

Vipshop Hlds

Voyager Therapeutics

Algoma Steel Group

Catalyst Pharmaceuticals

Momo

As a rule of thumb, you want to buy quality names in the market, which admittedly rules out several ideas for best stocks under $15 for June. It's not that cheap securities don't exist.

The 7 Best Stocks Under $15 to Buy in June 2023

EMERYVILLE, Calif. , May 8, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, at 1:00 p.m.

Dynavax to Present at the JMP Securities Life Sciences Conference

Dynavax Technologies Corporation (NASDAQ:DVAX ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Paul Cox - VP of IR and Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - CFO Conference Call Participants Matthew Phipps - William Blair Joshua Schimmer - Evercore ISI Roy Buchanan - JMP Securities Ed White - H.C. Wainwright Ernie Rodriguez - TD Cowen Operator Good day ladies and gentlemen.

Dynavax Technologies Corporation (DVAX) Q1 2023 Earnings Call Transcript

Dynavax Technologies (DVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.22 per share a year ago.

Dynavax Technologies (DVAX) Reports Q1 Loss, Tops Revenue Estimates

HEPLISAV-B ® vaccine net product revenue increased 109% year-over-year to $43.5 million in the first quarter of 2023 Reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $165–$185 million, representing annual revenue growth of 30-47% Strengthened balance sheet with cash and investments of $652 million at quarter end and expects positive free cash flow in 2023 Conference call today at 4:30 p.m. ET/1:30 p.m.

Dynavax Reports First Quarter 2023 Financial Results

EMERYVILLE, Calif. , April 18, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2023 financial results on Tuesday, May 2, 2023, after the U.S. financial markets close.

Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023

Aptevo Therapeutics

Beam Therapeutics

Chimerix

iTeos Therapeutics, Inc.

Kiniksa Pharmaceuticals Ltd

Vir Biotechnology

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

The Top 7 Growth Stocks in Biotech

Valneva SE

Saint - Herblain ( France), March 2 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001. As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership1. It is, however, completing remaining clinical studies and submissions as agreed with regulators.

Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001

EMERYVILLE, Calif. , March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Kelly MacDonald, Chief Financial Officer, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, at 2:10 p.m.

Dynavax to Present at the Cowen 43rd Annual Health Care Conference

HEPLISAV B is the only two-dose adult hepatitis B vaccine offering protection in just one month EMERYVILLE, Calif. , Feb. 28, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorization in Great Britain for HEPLISAV B (Hepatitis B Vaccine (Recombinant), Adjuvanted) for the active immunization against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine

Dynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2022 Results Conference Call February 23, 2023 4:30 PM ET Company Participants Nicole Arndt - Senior Manager, IR Ryan Spencer - CEO Donn Casale - SVP, Commercial Rob Janssen - Chief Medical Officer Kelly MacDonald - CFO Conference Call Participants Phil Nadeau - Cowen & Company Madhu Kumar - Goldman Sachs Matthew Phipps - William Blair Roy Buchanan - JMP Securities Operator Good day, ladies and gentlemen, and welcome to the Dynavax Technologies Fourth Quarter and Full Year 2022 Financial Results. As a reminder, this conference call is being recorded.

Dynavax Technologies Corporation (DVAX) Q4 2022 Earnings Call Transcript

2022 total revenue of $723 million, up 64% from $439 million in 2021 HEPLISAV-B ®  vaccine net product revenue of $126 million, representing 104% growth compared to 2021 CpG 1018® adjuvant vaccine net product revenue of $588 million 2023 HEPLISAV-B net product revenue anticipated to be between $ 165 million and $185 million, representing year-over-year revenue growth of approximately 30-47% Increased strength of  financial position with year-end cash and investments of $624 million Conference call today at 4:30 p.m. ET/1:30 p.m.

Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance

The consensus price target hints at a 109.6% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 109.61% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?

EMERYVILLE, Calif. , Feb. 9, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after the U.S. financial markets close.

Dynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Dynavax Technologies (DVAX) Upgraded to Strong Buy: Here's What You Should Know

EMERYVILLE, Calif. , Jan. 31, 2023 /PRNewswire/ -- Dynavax Technologies Corporation  (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced that effective as of market open today, January 31, 2023, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "DVAX".

Dynavax Announces Uplisting to the Nasdaq Global Select Market

The average of price targets set by Wall Street analysts indicates a potential upside of 103.2% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Dynavax Technologies Stock (DVAX)